News >

Immunotherapy Transforms Frontline Stage IV Squamous NSCLC Treatment

Ellie Leick
Published: Monday, Aug 12, 2019

Jennifer W. Carlisle, MD

Jennifer W. Carlisle, MD

The combination of immunotherapy and chemotherapy has moved to the frontline setting for patients with stage IV squamous non–small cell lung cancer (NSCLC), supported by findings of pivotal studies, such as KEYNOTE-407, explained Jennifer W. Carlisle, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication